Published in Medicine and Law Weekly, December 9th, 2005
The Series A investment in Allozyne was led by a syndicate of investors: Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, MPM Capital and OVP Venture Partners.
Allozyne was founded to commercialize proprietary technologies developed in the laboratories of David Tirrell and William Goddard at Caltech. These technologies will enable the company to improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics. This is achieved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly